CY1108701T1 - Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης. - Google Patents
Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης.Info
- Publication number
- CY1108701T1 CY1108701T1 CY20091100020T CY091100020T CY1108701T1 CY 1108701 T1 CY1108701 T1 CY 1108701T1 CY 20091100020 T CY20091100020 T CY 20091100020T CY 091100020 T CY091100020 T CY 091100020T CY 1108701 T1 CY1108701 T1 CY 1108701T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cell
- selectin glycoprotein
- regulators
- induce
- cells
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000008212 P-Selectin Human genes 0.000 abstract 1
- 108010035766 P-Selectin Proteins 0.000 abstract 1
- 230000033540 T cell apoptotic process Effects 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 230000026762 natural killer cell apoptotic process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31019601P | 2001-08-03 | 2001-08-03 | |
| US10/051,497 US7744888B2 (en) | 2001-08-03 | 2002-01-18 | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| EP02733839A EP1411982B1 (en) | 2001-08-03 | 2002-03-13 | Modulators of p-selectin glycoprotein ligand 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108701T1 true CY1108701T1 (el) | 2014-04-09 |
Family
ID=26729479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100020T CY1108701T1 (el) | 2001-08-03 | 2009-01-13 | Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης. |
| CY20121100115T CY1112966T1 (el) | 2001-08-03 | 2012-02-01 | Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100115T CY1112966T1 (el) | 2001-08-03 | 2012-02-01 | Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7744888B2 (enExample) |
| EP (2) | EP1411982B1 (enExample) |
| JP (3) | JP4815101B2 (enExample) |
| KR (1) | KR100850731B1 (enExample) |
| CN (2) | CN101045161B (enExample) |
| AT (2) | ATE411045T1 (enExample) |
| AU (1) | AU2002305041B2 (enExample) |
| CA (1) | CA2428822C (enExample) |
| CY (2) | CY1108701T1 (enExample) |
| DE (1) | DE60229394D1 (enExample) |
| DK (2) | DK1411982T3 (enExample) |
| ES (2) | ES2316569T3 (enExample) |
| IL (4) | IL160168A0 (enExample) |
| MX (1) | MXPA04001047A (enExample) |
| NO (2) | NO333456B1 (enExample) |
| NZ (1) | NZ531199A (enExample) |
| PT (2) | PT1985634E (enExample) |
| TW (1) | TWI327070B (enExample) |
| WO (1) | WO2003013603A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| AU2004273807B2 (en) * | 2003-09-15 | 2011-06-09 | Abgenomics Cooperatief U.A. | Modulators of P-Selectin Glycoprotein Ligand 1 |
| US7459523B2 (en) * | 2003-11-12 | 2008-12-02 | Wisconsin Alumni Research Foundation | Equine P-selectin glycoprotein ligand-1 and uses thereof |
| UY28886A1 (es) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| AU2012201999C1 (en) * | 2004-05-10 | 2016-05-12 | Abgenomics Cooperatief U.A. | Antibodies |
| BRPI0510561A (pt) * | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| WO2007033959A2 (en) * | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
| US20070160601A1 (en) * | 2005-12-09 | 2007-07-12 | Angela Widom | Neutralizing antibodies against primate psgl-1 and uses therefor |
| AU2009246166B2 (en) * | 2008-05-15 | 2014-09-18 | Tetherex Pharmaceuticals Corporation | Anti-PSGL-1 antibodies and methods of identification and use |
| ES2387156B1 (es) * | 2010-12-01 | 2013-07-04 | Universidad Autónoma de Madrid | Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes |
| CN116063522A (zh) | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| EP3881863A1 (en) * | 2014-07-08 | 2021-09-22 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
| ES2880731T3 (es) | 2016-01-08 | 2021-11-25 | Altrubio Inc | Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos |
| US20170241415A1 (en) * | 2016-02-19 | 2017-08-24 | Muzan, Inc. | Sanitary check valve |
| JP7244422B2 (ja) | 2017-01-11 | 2023-03-22 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｓｇｌ－１アンタゴニスト及びその使用 |
| SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| CN118994395A (zh) | 2018-07-20 | 2024-11-22 | 皮埃尔法布雷医药公司 | Vista受体 |
| WO2020224450A1 (en) * | 2019-05-03 | 2020-11-12 | The University Of Hong Kong | Method for peritoneal metastatic cell detection and isolation thereof |
| TW202110891A (zh) * | 2019-06-04 | 2021-03-16 | 美商維西歐製藥公司 | 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途 |
| WO2025168211A1 (en) * | 2023-02-10 | 2025-08-14 | Novo Nordisk A/S | P-selectin peptide ligands |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
| US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| WO1994014836A1 (en) | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| ES2126742T3 (es) | 1993-01-25 | 1999-04-01 | Dana Farber Cancer Inst Inc | Selectinas quimericas obtenidas mediante intercambio de dominios - sus usos. |
| WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| US5686426A (en) * | 1994-11-17 | 1997-11-11 | Bristol-Myers Squibb Company | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors |
| ES2208759T3 (es) | 1995-08-03 | 2004-06-16 | Board Of Regents Of The University Of Oklahoma | O-glicanos inhibidores de la inflamacion mediada por selectina. |
| JPH09227410A (ja) | 1996-02-21 | 1997-09-02 | Sumitomo Pharmaceut Co Ltd | 臓器移植拒絶反応の抑制剤 |
| WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
| NZ528610A (en) | 1998-10-30 | 2005-03-24 | Inst Genetics Llc | Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists |
| US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| JP2005503756A (ja) | 2000-12-29 | 2005-02-10 | サビエント ファーマシューティカルズ，インコーポレイティド | 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用 |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20050152906A1 (en) * | 2003-06-30 | 2005-07-14 | Avigdor Levanon | Specific human antibodies |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| BRPI0510561A (pt) | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| CN116063522A (zh) | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
-
2002
- 2002-01-18 US US10/051,497 patent/US7744888B2/en not_active Expired - Fee Related
- 2002-03-13 CN CN200710003904XA patent/CN101045161B/zh not_active Expired - Fee Related
- 2002-03-13 AT AT02733839T patent/ATE411045T1/de active
- 2002-03-13 KR KR1020047001711A patent/KR100850731B1/ko not_active Expired - Fee Related
- 2002-03-13 DK DK02733839T patent/DK1411982T3/da active
- 2002-03-13 CN CNB028029844A patent/CN1304051C/zh not_active Expired - Fee Related
- 2002-03-13 PT PT08012718T patent/PT1985634E/pt unknown
- 2002-03-13 NZ NZ531199A patent/NZ531199A/en not_active IP Right Cessation
- 2002-03-13 JP JP2003518607A patent/JP4815101B2/ja not_active Expired - Fee Related
- 2002-03-13 AT AT08012718T patent/ATE531734T1/de active
- 2002-03-13 MX MXPA04001047A patent/MXPA04001047A/es active IP Right Grant
- 2002-03-13 WO PCT/US2002/007498 patent/WO2003013603A1/en not_active Ceased
- 2002-03-13 ES ES02733839T patent/ES2316569T3/es not_active Expired - Lifetime
- 2002-03-13 DE DE60229394T patent/DE60229394D1/de not_active Expired - Lifetime
- 2002-03-13 EP EP02733839A patent/EP1411982B1/en not_active Expired - Lifetime
- 2002-03-13 IL IL16016802A patent/IL160168A0/xx active IP Right Grant
- 2002-03-13 AU AU2002305041A patent/AU2002305041B2/en not_active Ceased
- 2002-03-13 CA CA2428822A patent/CA2428822C/en not_active Expired - Lifetime
- 2002-03-13 EP EP08012718A patent/EP1985634B1/en not_active Expired - Lifetime
- 2002-03-13 DK DK08012718.6T patent/DK1985634T3/da active
- 2002-03-13 PT PT02733839T patent/PT1411982E/pt unknown
- 2002-03-13 ES ES08012718T patent/ES2376948T3/es not_active Expired - Lifetime
- 2002-04-10 TW TW091107216A patent/TWI327070B/zh not_active IP Right Cessation
-
2004
- 2004-02-02 NO NO20040460A patent/NO333456B1/no not_active IP Right Cessation
- 2004-02-02 IL IL160168A patent/IL160168A/en unknown
-
2008
- 2008-03-07 JP JP2008058501A patent/JP2008260759A/ja not_active Abandoned
-
2009
- 2009-01-13 CY CY20091100020T patent/CY1108701T1/el unknown
- 2009-06-29 US US12/494,018 patent/US8298540B2/en not_active Expired - Fee Related
-
2010
- 2010-02-18 IL IL204030A patent/IL204030A/en active IP Right Grant
-
2011
- 2011-01-11 IL IL210557A patent/IL210557A0/en unknown
-
2012
- 2012-02-01 CY CY20121100115T patent/CY1112966T1/el unknown
- 2012-02-03 JP JP2012022511A patent/JP2012092144A/ja active Pending
- 2012-09-14 US US13/616,749 patent/US8557579B2/en not_active Expired - Fee Related
-
2013
- 2013-01-14 NO NO20130069A patent/NO334850B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108701T1 (el) | Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης. | |
| WO2005027831A3 (en) | Modulators of p-selectin glycoprotein ligand 1 | |
| NO20060189L (no) | Antistoffer mot interleukin-22 og anvendelse derav | |
| CR7875A (es) | Variantes de inmunoglobina y usos de esto | |
| NO20053389D0 (no) | Antistoffer mot PD-1 og deres anvendelser. | |
| ES2187499T3 (es) | Metodos y aplicaciones para elementos supresores geneticos eficientes. | |
| PT966485E (pt) | Domínios de igg2 mutados não activantes e anticorpos anti-cd3 incorporando os mesmos | |
| DE60231665D1 (de) | Agarwood aus kulturmässigem Anbau | |
| PL339744A1 (en) | Azabenzimidazole based compounds useful in modulating action of serinic/treoninoic proteinic kinase | |
| DE60238801D1 (de) | Zelltrennungszusammensetzungen und -verfahren | |
| IN266744B (enExample) | ||
| DE60331583D1 (de) | Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen | |
| CY1107603T1 (el) | Χρηση της ανθρωπινης ορμονης αναπτυξης για την αυξηση του αριθμου των κυκλοφορουντων κυτταρων cd34+, με στοχο την ανασυνθεση των αιματοποιητικων και ανοσοποιητικων συστηματων ακολουθωντας μυελοβλαστικες ή αντιβλαστικες θepαπειες, μεσω μεταμοσχευσης, επαναμεταγγισης ή εμφυτευσης | |
| Gnatenko | ESTIMATING THE UPPER BOUND OF THE PARAMETER OF NONCOMMUTATIVITY ON THE BASIS OF THE EQUIVALENCE PRINCIPLE. | |
| SG146670A1 (en) | Modulators of p-selectin glycoprotein ligand 1 | |
| MX9204714A (es) | Depurador de fluidos mejorado y metodo para convertir el mismo entre los modos motorizado y manual. | |
| ATE469552T1 (de) | VERWENDUNG VON CNI-OD-FORMULIERUNGEN ZUR BEKÄMPFUNG DER WEIßEN FLIEGE | |
| SE8305444L (sv) | Bakterieavvisande ytor | |
| ATE278461T1 (de) | Mikropartikel hergestellt aus cycloolefincopolymeren und deren verwendung zur kontrollierten wirkstofffreigabe | |
| YU47378B (sh) | Suspenzija zeolita koja sadrži silikonsku smolu | |
| Shastri | Bharatiya Jyotish | |
| Szlufcik et al. | Modulation of inositol 1, 4, 5-trisphosphate receptor type 1 activity by thimerosal and calcium | |
| Miller | Eyes of the Mole (Book Review) | |
| Teimoorinia et al. | Astronomy as Science, Art and Industry | |
| Janča et al. | Mikrotermální field-flow frakcionace bakterií |